Precise execution

MC Services is...

Client News



… an international Corporate Communications and Investor Relations firm providing high-level consultancy with targeted services and support for transaction-oriented assignments throughout Europe and the United States.


read more


MC Services one of the main sponsors of the 9th DVFA Life Science Conference 2016

MC Services was once again one of the main sponsors of the 9th DVFA Life Science Conference, which took place in Frankfurt on June 14, 2016. Over recent years the DVFA Life Science Conference has become a highly valued platform to discuss new innovative technologies, therapies and products with financial market participants.

This year’s conference titled "Next Level Targeted Therapies – Game Changing Technologies for Future Medicine" focused on innovative treatment strategies and new therapies that have the potential to significantly change the treatment environment. Such a shift in cancer treatment includes immuno-oncology therapies, directing the immune system to eliminate tumor cells, libraries of highly specific and efficient antibodies against a broad portfolio of targets and personalized T-cell immunotherapies that are just some of the key developments in this field. MC Services’ clients have taken leading roles in the development of innovative approaches and exploring new ways of fighting cancer with the potential to transform current treatment approaches.


read more


MC Services sponsors Best Technology Award at the 2016 European Mediscience Awards

MC Services proudly contributed to this year’s European Mediscience Awards as sponsor of the Best Technology Award, for innovative technology that is well funded and capable of significant commercial success.


Mediscience Awards 2016: The winners have been crowned

It is done: after much anticipation the winners of the 2016 Mediscience Awards have been crowned! A huge congratulation to all the winners & shortlisted companies!

read more


Please also follow us on Twitter (@MCServicesAG)

RedHill Biopharma Receives Additional U.S. Patent Covering RHB-105 Ahead of Confirmatory Phase III Study for H. pylori Infection


Medigene expands TCR platform technology with US patent for method for identification of CD4+ T cell antigens


Result of General Meeting; Appointment of Directors; Total Voting Rights; Application for Block Listing


InflaRx raises EUR 31 million (US$ 34M) in a Series C financing round to foster complement inhibitor development


Transgene to Continue Phase 1/1b Study with TG1050 in Chronic Hepatitis B Patients on the Recommendation of the Trial’s Safety Review Committee


Newron Pharmaceuticals Announces Initiation of the STARS Study in the United States Potentially Pivotal Study to Evaluate Sarizotan for the Treatment of Apneas in Rett Syndrome


Adocia presents first half 2016 financial results


Nextech Invest Closes Oncology Fund IV


4SC forms international Scientific Expert Panel


Apogenix Granted European Patent for the Use of APG101 in the Treatment of Myelodysplastic Syndromes


Neovacs and Stellar Biotechnologies Announce Launch of Neostell, Joint Venture to Manufacture Kinoids


RedHill Biopharma Announces Research Collaboration with NIH for Potential Ebola Treatment


RedHill Biopharma and IntelGenx Announce Definitive Agreement for Commercialization of RIZAPORT(TM) for Migraines with Grupo JUSTE in Spain and Additional Potential Territories